Related references
Note: Only part of the references are listed.Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
Parakkal Deepak et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry
Maria Chaparro et al.
JOURNAL OF CROHNS & COLITIS (2021)
Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis
Tessa Straatmijer et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2021)
Perioperative safety of tofacitinib in surgical ulcerative colitis patients
Amy L. Lightner et al.
COLORECTAL DISEASE (2021)
Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
Hiromichi Shimizu et al.
INTESTINAL RESEARCH (2021)
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis
Loriane Lair-Mehiri et al.
DIGESTIVE AND LIVER DISEASE (2020)
First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
Siddharth Singh et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis
Pablo Olivera et al.
GASTROENTEROLOGY (2020)
P399 Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: A prospective real-life cohort
B Verstockt et al.
Journal of Crohns & Colitis (2020)
P512 Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data
Y XIAO et al.
Journal of Crohns & Colitis (2020)
P684 The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme
B E Sands et al.
Journal of Crohns & Colitis (2020)
P422 Tofacitinib induces clinical and endoscopic remission in biologic refractory ulcerative colitis patients: a real-world Belgian cohort study
A Cremer et al.
Journal of Crohns & Colitis (2020)
P663 Efficacy of tofacitinib in patients with ulcerative colitis after previous ineffective biological therapies
M Rutka et al.
Journal of Crohns & Colitis (2020)
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
Vince B. C. Biemans et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Tu1857 TOFACITINIB, AN ORAL, SMALL MOLECULE JANUS KINASE INHIBITOR, IN THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF AN OPEN-LABEL, LONG-TERM EXTENSION STUDY WITH UP TO 5.9 YEARS OF TREATMENT
Gary R. Lichtenstein et al.
GASTROENTEROLOGY (2020)
Su1857 SAFETY OF TOFACITINIB ON POSTOPERATIVE OUTCOMES AFTER SUBTOTAL COLECTOMY IN ULCERATIVE COLITIS
Haluk T. Kani et al.
GASTROENTEROLOGY (2020)
Tu1907 EFFICACY INCLUDING RAPID RESPONSE AND SAFETY OF TOFACITINIB IN JAPANESE PATIENTS WITH ULCERATIVE COLITIS: A PRELIMINARY INVESTIGATION IN A SPECIALIZED IBD CENTER
Kenji Watanabe et al.
GASTROENTEROLOGY (2020)
Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience
Sailish Honap et al.
JOURNAL OF CROHNS & COLITIS (2020)
Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study
Peter Hoffmann et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study
R. Ungaro et al.
JOURNAL OF CROHNS & COLITIS (2019)
Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
Christopher Ma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
William J. Sandborn et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
ACG Clinical Guideline: Ulcerative Colitis in Adults
David T. Rubin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
Safety and efficacy of tofacitinib for up to 9.5years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study
Juergen Wollenhaupt et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
F. Valenzuela et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review
Mathurin Fumery et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
Bruce E. Sands et al.
JOURNAL OF CROHNS & COLITIS (2018)
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
Stefan Schreiber et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors
Abril Verden et al.
DRUG SAFETY (2018)
Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis
S. Bonovas et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Sudarshan Paramsothy et al.
JOURNAL OF CROHNS & COLITIS (2017)
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Stanley B. Cohen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis
L. Peyrin-Biroulet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study
Mike van der Have et al.
JOURNAL OF CROHNS & COLITIS (2016)
Comparing disease activity indices in ulcerative colitis
A. J. Walsh et al.
JOURNAL OF CROHNS & COLITIS (2014)
Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis
Vincent Billioud et al.
JOURNAL OF CROHNS & COLITIS (2013)
Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population
Louise K. Mercer et al.
RHEUMATOLOGY (2013)
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
Treating Individuals 1 - External validity of randomised controlled trials: To whom do the results of this trial apply?'
PM Rothwell
LANCET (2005)
Long-term Risk of Cancer in Ulcerative Colitis: A Population-Based Cohort Study From Copenhagen County
Karen V. Winther et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
A new system for grading recommendations in evidence based guidelines
R Harbour et al.
BRITISH MEDICAL JOURNAL (2001)
Share Paper
